[go: up one dir, main page]

SV2018005661A - Composiciones oligonucleotidicas y sus metodos - Google Patents

Composiciones oligonucleotidicas y sus metodos

Info

Publication number
SV2018005661A
SV2018005661A SV2018005661A SV2018005661A SV2018005661A SV 2018005661 A SV2018005661 A SV 2018005661A SV 2018005661 A SV2018005661 A SV 2018005661A SV 2018005661 A SV2018005661 A SV 2018005661A SV 2018005661 A SV2018005661 A SV 2018005661A
Authority
SV
El Salvador
Prior art keywords
compositions
oligonucleotydic
ways
methods
realization
Prior art date
Application number
SV2018005661A
Other languages
English (en)
Inventor
Butler David Charles Donell
Sethumadhavan Divakaremenon
Christopher J Francis
-Kamenetsky Maria David Frank
Naoki Iwamoto
Genliang Lu
Subramanian Marappan
Mena
Chandra Vargeese
Gregory L Verdine
Hailin Yang
Jason Jingxin Zhang
Original Assignee
Wave Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wave Life Sciences Ltd filed Critical Wave Life Sciences Ltd
Publication of SV2018005661A publication Critical patent/SV2018005661A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/59—Hydrogenated pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3533—Halogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

ENTRE OTRAS COSAS, LA PRESENTE REVELACIÓN SE REFIERE A OLIGONUCLEÓTIDOS, COMPOSICIONES DISEÑADOS Y SUS MÉTODOS. EN ALGUNAS FORMAS DE REALIZACIÓN, LAS COMPOSICIONES OLIGONUCLEOTÍDICAS PROPORCIONADAS SUMINISTRAN UN EMPALME ALTERADO DE UN TRANSCRIPTO. EN ALGUNAS FORMAS DE REALIZACIÓN, LAS COMPOSICIONES OLIGONUCLEOTÍDICAS PROPORCIONADAS TIENEN BAJA TOXICIDAD. EN ALGUNAS FORMAS DE REALIZACIÓN, LAS COMPOSICIONES OLIGONUCLEOTÍDICAS PROPORCIONADAS SUMINISTRAN MEJORES PERFILES DE LIGACIÓN DE PROTEÍNAS.EN ALGUNAS FORMAS DE REALIZACIÓN, LAS COMPOSICIONES OLIGONUCLEOTÍDICAS PROPORCIONADAS TIENEN MEJOR SUMINISTRO. EN ALGUNAS FORMAS DE REALIZACIÓN, LAS COMPOSICIONES OLIGONUCLEOTÍDICAS PROPORCIONADAS TIENEN MEJOR CAPTACIÓN. EN ALGUNAS FORMAS DE REALIZACIÓN, LA PRESENTE REVELACIÓN PROPORCIONA MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES USANDO COMPOSICIONES PROPORCIONADAS OLIGONUCLEOTÍDICAS
SV2018005661A 2015-10-09 2018-04-04 Composiciones oligonucleotidicas y sus metodos SV2018005661A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562239839P 2015-10-09 2015-10-09
US201662331966P 2016-05-04 2016-05-04
US201662331961P 2016-05-04 2016-05-04

Publications (1)

Publication Number Publication Date
SV2018005661A true SV2018005661A (es) 2018-09-25

Family

ID=58488684

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2018005661A SV2018005661A (es) 2015-10-09 2018-04-04 Composiciones oligonucleotidicas y sus metodos

Country Status (22)

Country Link
US (4) US20190127733A1 (es)
EP (2) EP3359523A4 (es)
JP (4) JP7511326B2 (es)
KR (1) KR20180056766A (es)
CN (3) CN114533900A (es)
AU (4) AU2016334232B2 (es)
BR (1) BR112018006636B1 (es)
CA (2) CA2999772A1 (es)
CL (1) CL2018000818A1 (es)
CO (1) CO2018004758A2 (es)
CR (1) CR20180233A (es)
EC (1) ECSP18032914A (es)
IL (2) IL295755A (es)
MA (2) MA46427A (es)
MX (2) MX2018003992A (es)
NI (1) NI201800045A (es)
PE (1) PE20181353A1 (es)
PH (1) PH12018500719A1 (es)
SG (1) SG10201912902TA (es)
SV (1) SV2018005661A (es)
TW (1) TW201722439A (es)
WO (2) WO2017062862A2 (es)

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158768B2 (en) * 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
KR101881596B1 (ko) 2008-12-02 2018-07-24 웨이브 라이프 사이언시스 재팬 인코포레이티드 인 원자 변형된 핵산의 합성 방법
BR112012000828A8 (pt) 2009-07-06 2017-10-10 Ontorii Inc Novas pró-drogas de ácido nucleico e métodos de uso das mesmas
WO2012039448A1 (ja) 2010-09-24 2012-03-29 株式会社キラルジェン 不斉補助基
BR112014001244A2 (pt) 2011-07-19 2017-02-21 Wave Life Sciences Pte Ltd métodos para a síntese de ácidos nucléicos funcionalizados
RU2015104762A (ru) 2012-07-13 2018-08-31 Уэйв Лайф Сайенсес Лтд. Хиральный контроль
BR112015000784A8 (pt) 2012-07-13 2018-04-03 Wave Life Sciences Japan Grupo auxiliar assimétrico
WO2015108047A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
WO2015108048A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
WO2015107425A2 (en) 2014-01-16 2015-07-23 Wave Life Sciences Pte. Ltd. Chiral design
DK3234134T3 (da) 2014-12-17 2020-07-27 Proqr Therapeutics Ii Bv Målrettet rna-redigering
EP3929293A3 (en) 2015-04-03 2022-03-16 University Of Massachusetts Fully stabilized asymmetric sirna
MA43072A (fr) 2015-07-22 2018-05-30 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
EP3334499A4 (en) 2015-08-14 2019-04-17 University of Massachusetts BIOACTIVE CONJUGATES FOR THE RELEASE OF OLIGONUCLEOTIDES
MA46427A (fr) * 2015-10-09 2018-08-15 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
DK4279084T3 (da) 2015-10-28 2025-09-15 Vertex Pharma Materialer og fremgangsmåder til behandling af duchennes muskeldystrofi
CA3011894A1 (en) 2016-01-31 2017-08-03 University Of Massachusetts Branched oligonucleotides
CA3015823A1 (en) 2016-03-13 2017-09-21 Wave Life Sciences Ltd. Compositions and methods for phosphoramidite and oligonucleotide synthesis
MA45270A (fr) 2016-05-04 2017-11-09 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
JP2019520339A (ja) 2016-06-03 2019-07-18 ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． オリゴヌクレオチド、その組成物および方法
KR102418185B1 (ko) 2016-06-22 2022-07-06 프로큐알 테라퓨틱스 Ⅱ 비.브이. 단일 가닥 rna-편집 올리고뉴클레오타이드
MX2018016253A (es) 2016-07-05 2019-09-09 Biomarin Tech Bv Oligonucleotidos de conmutacion o modulacion de empalme de pre-arnm que comprenden radicales de andamio biciclicos, con caracteristicas mejoradas para el tratamiento de trastornos geneticos.
US11753638B2 (en) 2016-08-12 2023-09-12 University Of Massachusetts Conjugated oligonucleotides
ES2837076T3 (es) 2016-09-01 2021-06-29 Proqr Therapeutics Ii Bv Oligonucleótidos para la edición de ARN de cadena sencilla modificados químicamente
EP3544987A4 (en) 2016-11-23 2020-11-18 Wave Life Sciences Ltd. COMPOSITIONS AND SYNTHESIS OF PHOSPHORAMIDITES AND OLIGONUCLEOTIDES
AU2017382773B2 (en) 2016-12-19 2025-01-30 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
KR102552428B1 (ko) 2016-12-19 2023-07-06 사렙타 쎄러퓨틱스 인코퍼레이티드 근육 이상증에 대한 엑손 스킵핑 올리고머 결합체
LT4122497T (lt) 2016-12-19 2024-06-10 Sarepta Therapeutics, Inc. Egzonus praleidžiantys oligomerų konjugatai, skirti raumenų distrofijai gydyti
WO2018161032A1 (en) 2017-03-03 2018-09-07 The Regents Of The University Of California RNA TARGETING OF MUTATIONS VIA SUPPRESSOR tRNAs AND DEAMINASES
CN111050806A (zh) * 2017-06-02 2020-04-21 波涛生命科学有限公司 寡核苷酸组合物及其使用方法
JP7557941B2 (ja) * 2017-06-02 2024-09-30 ウェイブ ライフ サイエンシズ リミテッド オリゴヌクレオチド組成物及びその使用方法
CN120330183A (zh) * 2017-06-02 2025-07-18 波涛生命科学有限公司 寡核苷酸组合物及其使用方法
WO2018237194A1 (en) 2017-06-21 2018-12-27 Wave Life Sciences Ltd. Compounds, compositions and methods for synthesis
CN110799647A (zh) 2017-06-23 2020-02-14 马萨诸塞大学 双尾自递送sirna及相关的方法
AR112779A1 (es) * 2017-08-08 2019-12-11 Wave Life Sciences Ltd Composiciones de nucleótidos y métodos relacionados
AU2018333065B2 (en) 2017-09-18 2024-04-18 Wave Life Sciences Ltd. Technologies for oligonucleotide preparation
EA201991450A1 (ru) 2017-09-22 2019-12-30 Сарепта Терапьютикс, Инк. Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
JP2020536057A (ja) 2017-09-28 2020-12-10 サレプタ セラピューティクス， インコーポレイテッド 筋ジストロフィーを処置するための併用療法
US20210145852A1 (en) 2017-09-28 2021-05-20 Sarepta Therapeutics, Inc. Combination Therapies for Treating Muscular Dystrophy
US20200248178A1 (en) 2017-09-28 2020-08-06 Sarepta Therapeutics, Inc. Combination therapies for treating muscular dystrophy
JP2020537518A (ja) * 2017-10-12 2020-12-24 ウェーブ ライフ サイエンシーズ リミテッド オリゴヌクレオチド組成物及びその方法
CA3086485A1 (en) * 2017-12-21 2019-06-27 Alnylam Pharmaceuticals, Inc. Chirally-enriched double-stranded rna agents
WO2019176939A1 (ja) 2018-03-15 2019-09-19 栄研化学株式会社 一塩基多型検出用オリゴヌクレオチドプローブ、及びシス型－トランス型判別方法
IL314987A (en) * 2018-04-12 2024-10-01 Wave Life Sciences Ltd Preparations of oligonucleotides and methods of using them
BR112020022546A8 (pt) 2018-05-07 2022-05-17 Alnylam Pharmaceuticals Inc Entrega extra-hepática
CN112218664A (zh) * 2018-05-11 2021-01-12 波涛生命科学有限公司 寡核苷酸组合物及其使用方法
GB201808146D0 (en) 2018-05-18 2018-07-11 Proqr Therapeutics Ii Bv Stereospecific Linkages in RNA Editing Oligonucleotides
US10758629B2 (en) 2018-05-29 2020-09-01 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
EP4219717A3 (en) 2018-06-13 2023-12-20 Sarepta Therapeutics, Inc. Exon skipping oligomers for muscular dystrophy
TW202020153A (zh) 2018-07-27 2020-06-01 美商薩羅塔治療公司 用於肌肉萎縮症之外顯子跳躍寡聚物
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US20210308273A1 (en) 2018-08-02 2021-10-07 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
WO2020028864A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
WO2020041769A1 (en) * 2018-08-23 2020-02-27 University Of Massachusetts O-methyl rich fully stabilized oligonucleotides
EP3874044A1 (en) 2018-11-02 2021-09-08 BioMarin Technologies B.V. Bispecific antisense oligonucleotides for dystrophin exon skipping
JP2022513719A (ja) * 2018-12-06 2022-02-09 ウェイブ ライフ サイエンシズ リミテッド オリゴヌクレオチド組成物及びその方法
EA202191601A1 (ru) 2018-12-13 2022-01-19 Сарепта Терапьютикс, Инк. Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
WO2020150636A1 (en) 2019-01-18 2020-07-23 University Of Massachusetts Dynamic pharmacokinetic-modifying anchors
US20220193246A1 (en) 2019-04-18 2022-06-23 Sarepta Therapeutics, Inc. Compositions for treating muscular dystrophy
WO2020219983A2 (en) * 2019-04-25 2020-10-29 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
AU2020261434A1 (en) * 2019-04-25 2021-11-11 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
KR20220047989A (ko) 2019-08-09 2022-04-19 유니버시티 오브 매사추세츠 Snp를 표적화하는 화학적으로 변형된 올리고뉴클레오타이드
US20210115442A1 (en) * 2019-08-23 2021-04-22 University Of Massachusetts O-methyl rich fully stabilized oligonucleotides
US12365894B2 (en) 2019-09-16 2025-07-22 University Of Massachusetts Branched lipid conjugates of siRNA for specific tissue delivery
CA3151789A1 (en) * 2019-09-19 2021-03-25 Arnay Sciences, Llc Compounds and methods useful for modulating gene splicing
US20220340903A1 (en) * 2019-09-25 2022-10-27 University Of Massachusetts Targeting rlim to modulate body weight and obesity
CA3154768A1 (en) * 2019-10-06 2021-04-15 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
MX2022004102A (es) * 2019-10-06 2022-04-26 Wave Life Sciences Ltd Composiciones de oligonucleotidos y metodos de uso de las mismas.
US11827880B2 (en) 2019-12-02 2023-11-28 Shape Therapeutics Inc. Therapeutic editing
EP4081638A1 (en) 2019-12-23 2022-11-02 ProQR Therapeutics II B.V. Antisense oligonucleotides for nucleotide deamination in the treatment of stargardt disease
AU2020411964A1 (en) 2019-12-26 2022-06-16 National Center Of Neurology And Psychiatry Antisense nucleic acid that induces skipping of exon 50
CA3173049A1 (en) 2020-02-28 2021-09-02 Nippon Shinyaku Co., Ltd. Antisense nucleic acid inducing skipping of exon 51
IL298406A (en) 2020-05-22 2023-01-01 Wave Life Sciences Ltd Double stranded oligonucleotide compositions and methods relating thereto
EP4157289A4 (en) 2020-05-26 2024-06-26 University Of Massachusetts Synthetic oligonucleotides having regions of block and cluster modifications
KR20230079183A (ko) 2020-09-30 2023-06-05 바이오마린 테크놀로지스 비.브이. 디스트로핀 유전자의 엑손 51을 표적화하는 안티센스 올리고뉴클레오타이드
WO2022140702A1 (en) 2020-12-23 2022-06-30 Flagship Pioneering, Inc. Compositions of modified trems and uses thereof
AU2022267324A1 (en) 2021-04-30 2023-12-14 Sarepta Therapeutics, Inc. Treatment methods for muscular dystrophy
BR112023026862A2 (pt) 2021-06-23 2024-03-05 Beth Israel Deaconess Medical Ct Inc Compostos de oligonucleotídeos anti-flt1 otimizados para tratamento de pré-eclâmpsia e outros distúrbios angiogênicos
WO2023283623A1 (en) 2021-07-09 2023-01-12 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating dystrophinopathies
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
CA3226001A1 (en) 2021-07-16 2023-01-19 Anton Jan Van Zonneveld Oligonucleotide for inhibiting quaking activity
IL311568A (en) 2021-09-30 2024-05-01 Sarepta Therapeutics Inc Antisense oligonucleotides having one or more abasic units
TWI866002B (zh) * 2021-12-29 2024-12-11 財團法人生物技術開發中心 反義寡核苷酸及其用途
EP4215614A1 (en) 2022-01-24 2023-07-26 Dynacure Combination therapy for dystrophin-related diseases
US20250154504A1 (en) 2022-02-14 2025-05-15 Proqr Therapeutics Ii B.V. Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia
CN119013401A (zh) 2022-03-17 2024-11-22 萨勒普塔医疗公司 二氨基磷酸酯吗啉代寡聚物缀合物
IL316143A (en) 2022-04-15 2024-12-01 Dyne Therapeutics Inc Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
WO2023212369A1 (en) * 2022-04-29 2023-11-02 Singular Genomics Systems, Inc. Nucleotide cyclic cleavable moieties and uses thereof
PE20251277A1 (es) 2022-05-06 2025-05-14 Academisch Ziekenhuis Leiden Oligonucleotido
EP4282964A1 (en) * 2022-05-23 2023-11-29 Universitat de Valéncia Oligonucleotides conjugated to oleic acid and uses thereof
US20250179492A1 (en) 2022-06-22 2025-06-05 Flagship Pioneering Innovations Vi, Llc Compositions of modified trems and uses thereof
CA3262119A1 (en) 2022-07-15 2024-01-18 The Regents Of The University Of California OLIGONUCLEOTIDES FOR ADAR-MEDIATED RNA EDITING AND THEIR USE
EP4555085A1 (en) 2022-07-15 2025-05-21 ProQR Therapeutics II B.V. Chemically modified oligonucleotides for adar-mediated rna editing
EP4562145A1 (en) 2022-07-25 2025-06-04 Vico Therapeutics B.V. Antisense oligonucleotides for treating a disease or condition associated with an abnormal processing of app
JP2025533454A (ja) 2022-09-21 2025-10-07 サレプタ セラピューティクス， インコーポレイテッド Ｄｍｄアンチセンスオリゴヌクレオチド介在性エクソンスキッピング効率
GB202215614D0 (en) 2022-10-21 2022-12-07 Proqr Therapeutics Ii Bv Heteroduplex rna editing oligonucleotide complexes
TW202435897A (zh) 2022-11-24 2024-09-16 荷蘭商Ｐｒｏｑｒ治療上市公司Ｉｉ 用於治療遺傳性ｈｆｅ血色沉著病之反義寡核苷酸
GB202218090D0 (en) 2022-12-01 2023-01-18 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency
EP4630553A1 (en) 2022-12-09 2025-10-15 ProQR Therapeutics II B.V. Antisense oligonucleotides for the treatment of cardiovascular disease
GB202300865D0 (en) 2023-01-20 2023-03-08 Proqr Therapeutics Ii Bv Delivery of oligonucleotides
EP4669753A1 (en) 2023-02-20 2025-12-31 ProQR Therapeutics II B.V. Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease
WO2024196804A1 (en) * 2023-03-17 2024-09-26 The Regents Of The University Of California Factor viii splice-modulating antisense oligonucleotides and methods of use
WO2024206175A1 (en) 2023-03-24 2024-10-03 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of neurological disorders
GB202304363D0 (en) 2023-03-24 2023-05-10 Proqr Therapeutics Ii Bv Chemically modified antisense oligonucleotides for use in RNA editing
WO2024200472A1 (en) 2023-03-27 2024-10-03 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of liver disease
AR132529A1 (es) 2023-04-27 2025-07-16 Sarepta Therapeutics Inc Oligómeros antisentido para el tratamiento de la enfermedad renal crónica
WO2024243087A2 (en) * 2023-05-19 2024-11-28 Leverna Therapeutics Inc. Compositions and methods for regulating expression of atxn2
TW202516003A (zh) 2023-06-16 2025-04-16 荷蘭商Ｐｒｏｑｒ治療上市公司Ｉｉ 用於治療神經退化性疾病之反義寡核苷酸
AU2024287308A1 (en) 2023-07-13 2025-12-18 Korro Bio, Inc. Rna-editing oligonucleotides and uses thereof
WO2025028591A1 (ja) * 2023-08-02 2025-02-06 株式会社日本触媒 オリゴヌクレオチドの製造方法
WO2025042786A1 (en) 2023-08-18 2025-02-27 Flagship Pioneering Innovations Vi, Llc Compositions comprising circular polyribonucleotides and uses thereof
WO2025051946A1 (en) 2023-09-07 2025-03-13 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of metabolic disorders
WO2025085810A2 (en) 2023-10-18 2025-04-24 Sarepta Therapeutics, Inc. Antisense oligomers for treatment of centronuclear myopathies
AU2024369609A1 (en) 2023-10-31 2025-12-11 Korro Bio, Inc. Oligonucleotides comprising phosphoramidate internucleotide linkages
WO2025104239A1 (en) 2023-11-16 2025-05-22 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of classic galactosemia
US20250161347A1 (en) 2023-11-22 2025-05-22 Flagship Pioneering Innovations Vii, Llc Methods and compositions for treating non-alcoholic fatty liver disease
WO2025128799A1 (en) 2023-12-12 2025-06-19 Korro Bio, Inc. Double-stranded rna-editing oligonucleotides and uses thereof
WO2025132708A1 (en) 2023-12-20 2025-06-26 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of huntington's disease
GB202404661D0 (en) 2024-04-02 2024-05-15 Proqr Therapeutics Ii Bv Antisense oligoncleotides for the treatment of liver disease
WO2025224230A1 (en) 2024-04-25 2025-10-30 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of fatty liver disease
WO2025245188A2 (en) 2024-05-21 2025-11-27 Flagship Pioneering Innovations Vii, Llc Methods of treating liver steatosis and non-alcoholic fatty liver disease
GB202410081D0 (en) 2024-07-11 2024-08-28 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of cardiovascular disease
WO2026022136A1 (en) 2024-07-23 2026-01-29 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of metabolic disorders

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5852188A (en) * 1990-01-11 1998-12-22 Isis Pharmaceuticals, Inc. Oligonucleotides having chiral phosphorus linkages
JP2693643B2 (ja) * 1991-10-15 1997-12-24 アイシス・ファーマシューティカルス・インコーポレーテッド キラルリン結合を有するオリゴヌクレオチド
US5856465A (en) * 1996-05-24 1999-01-05 Polska Akademia Nauk Centrum Badan Molekularnych I Makromolekularnych Compositions and methods for the synthesis of chirally pure organophosphorus nucleoside derivatives
US5804384A (en) * 1996-12-06 1998-09-08 Vysis, Inc. Devices and methods for detecting multiple analytes in samples
US6242589B1 (en) * 1998-07-14 2001-06-05 Isis Pharmaceuticals, Inc. Phosphorothioate oligonucleotides having modified internucleoside linkages
US20020082227A1 (en) * 1999-09-30 2002-06-27 Scott Henry Use of oligonucleotides for inhibition of complement activation
EP1282699B1 (en) 2000-05-04 2012-11-21 Sarepta Therapeutics, Inc. Splice-region antisense composition and method
EP1191097A1 (en) 2000-09-21 2002-03-27 Leids Universitair Medisch Centrum Induction of exon skipping in eukaryotic cells
US6858720B2 (en) * 2001-10-31 2005-02-22 Agilent Technologies, Inc. Method of synthesizing polynucleotides using ionic liquids
AU2003291721A1 (en) * 2002-11-05 2004-06-03 Isis Pharmaceuticals, Inc. Phosphorous-linked oligomeric compounds and their use in gene modulation
CA2524255C (en) 2003-03-21 2014-02-11 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
US7598227B2 (en) 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
JP2005089441A (ja) 2003-08-08 2005-04-07 Toudai Tlo Ltd 立体規則性の高いリン原子修飾ヌクレオチド類縁体の製造法
WO2005023828A1 (ja) 2003-09-02 2005-03-17 Takeshi Wada リボヌクレオチド又はリボヌクレオチド誘導体の製造方法
JP4616175B2 (ja) 2003-09-02 2011-01-19 株式会社キラルジェン ５’−ホスフィチル化モノマーおよびｈ−ホスホネートオリゴヌクレオチド誘導体の製造方法
JP4945129B2 (ja) 2004-01-27 2012-06-06 株式会社キラルジェン フルオラス担体およびそれを用いたオリゴヌクレオチド誘導体の製造方法
WO2005085272A1 (ja) 2004-03-05 2005-09-15 Takeshi Wada ボラノホスフェートモノマーおよびそれを用いたオリゴヌクレオチド誘導体の製造方法
EP4272748A3 (en) 2004-06-28 2024-03-27 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
MX2007002214A (es) 2004-09-03 2007-05-07 Yuhan Corp Derivados de pirrolo[3,2-c]piridina y procesos para su preparacion.
WO2006096963A1 (en) * 2005-03-15 2006-09-21 Mcgill University Ionic liquid supported synthesis
NZ563206A (en) 2005-04-22 2009-09-25 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mRNA by interfering with the binding or SR proteins and by interfering with secondary RNA structure
WO2007123391A1 (en) 2006-04-20 2007-11-01 Academisch Ziekenhuis Leiden Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene.
US20130129752A1 (en) 2006-04-25 2013-05-23 Immune Disease Institute, Inc. Targeted delivery to leukocytes using protein carriers
US8097596B2 (en) 2006-06-30 2012-01-17 Lakewood-Amedex, Inc. Compositions and methods for the treatment of muscle wasting
EP2203173B1 (en) 2007-10-26 2015-12-23 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
WO2009142822A2 (en) * 2008-03-26 2009-11-26 Alnylam Pharmaceuticals, Inc. 2-f modified rna interference agents
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
US8084601B2 (en) 2008-09-11 2011-12-27 Royal Holloway And Bedford New College Royal Holloway, University Of London Oligomers
US20100105054A1 (en) 2008-10-15 2010-04-29 Cincinnati Children's Hospital Medical Center Gene expression in duchenne muscular dystrophy
SI3133160T1 (sl) 2008-10-24 2019-05-31 Sarepta Therapeutics, Inc. Sestavki, ki preskakujejo ekson za DMD
PT2607484E (pt) 2008-10-27 2016-03-09 Academisch Ziekenhuis Leiden Métodos e meios para o salto eficiente do exão 45 no pré-mrna de distrofia muscular de duchenne
KR101881596B1 (ko) 2008-12-02 2018-07-24 웨이브 라이프 사이언시스 재팬 인코포레이티드 인 원자 변형된 핵산의 합성 방법
US20120149756A1 (en) 2009-04-10 2012-06-14 Associatin Institut de Myologie Tricyclo-dna antisense oligonucleotides, compositions, and methods for the treatment of disease
US20120156138A1 (en) 2009-04-14 2012-06-21 Smith Larry J Methods and Compositions for the Treatment of Medical Conditions Involving Cellular Reprogramming
CA2761248C (en) 2009-05-08 2023-03-14 Joseph Collard Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
BR112012000828A8 (pt) 2009-07-06 2017-10-10 Ontorii Inc Novas pró-drogas de ácido nucleico e métodos de uso das mesmas
EP2479182B8 (en) 2009-09-16 2016-07-13 Wave Life Sciences Japan, Inc. Novel protecting group for synthesizing rna and derivative thereof
SMT201800579T1 (it) 2009-11-12 2019-01-11 Univ Western Australia Molecole antisenso e metodi per trattare patologie
WO2011064552A1 (en) 2009-11-30 2011-06-03 Isis Innovation Limited Conjugates for delivery of biologically active compounds
WO2011078797A2 (en) 2009-12-22 2011-06-30 Singapore Health Services Pte. Ltd Antisense oligonucleotides and uses threreof
US8859755B2 (en) 2010-03-05 2014-10-14 Chiralgen, Ltd. Method for preparing ribonucleoside phosphorothioate
US9518259B2 (en) * 2010-06-15 2016-12-13 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating interaction between proteins and target nucleic acids
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
WO2012039448A1 (ja) 2010-09-24 2012-03-29 株式会社キラルジェン 不斉補助基
EP3766975A1 (en) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
JP6093924B2 (ja) 2010-11-30 2017-03-15 株式会社Wave Life Sciences Japan ２’−ｏ−修飾ｒｎａ
US9078911B2 (en) 2011-02-08 2015-07-14 The Charlotte-Mecklenburg Hospital Authority Antisense oligonucleotides
DE102011005259A1 (de) * 2011-03-08 2012-09-13 Olympus Winter & Ibe Gmbh Verfahren und System zur Darstellung videoendoskopischer Bilddaten eines Videoendoskops
BR112014001244A2 (pt) 2011-07-19 2017-02-21 Wave Life Sciences Pte Ltd métodos para a síntese de ácidos nucléicos funcionalizados
EP3453761A1 (en) * 2011-08-29 2019-03-13 Ionis Pharmaceuticals, Inc. Oligomer-conjugate complexes and their use
US20140080896A1 (en) * 2011-08-30 2014-03-20 The Regents Of The University Of California Identification of small molecules that facilitate therapeutic exon skipping
CA2895077A1 (en) * 2011-12-12 2013-06-20 Beverly Packard In vivo delivery of oligonucleotides
CN108486116A (zh) 2011-12-28 2018-09-04 日本新药株式会社 反义核酸
ES2907250T3 (es) * 2012-01-27 2022-04-22 Biomarin Tech Bv Oligonucleótidos de modulación de ARN con características mejoradas para el tratamiento de la distrofia muscular de Duchenne y de Becker
EP3608407A1 (en) * 2012-07-03 2020-02-12 BioMarin Technologies B.V. Oligonucleotide for the treatment of muscular dystrophy patients
BR112015000784A8 (pt) 2012-07-13 2018-04-03 Wave Life Sciences Japan Grupo auxiliar assimétrico
BR112015000723A2 (pt) 2012-07-13 2017-06-27 Shin Nippon Biomedical Laboratories Ltd adjuvante de ácido nucléico quiral
RU2015104762A (ru) * 2012-07-13 2018-08-31 Уэйв Лайф Сайенсес Лтд. Хиральный контроль
HRP20190826T1 (hr) 2012-11-15 2019-06-28 Roche Innovation Center Copenhagen A/S Konjugati oligonukleotida
WO2014118272A1 (en) 2013-01-30 2014-08-07 Santaris Pharma A/S Antimir-122 oligonucleotide carbohydrate conjugates
CN105378081B (zh) 2013-03-14 2019-06-14 萨勒普塔医疗公司 用于治疗肌营养不良的外显子跳跃组合物
HK1220154A1 (zh) 2013-03-15 2017-04-28 Sarepta Therapeutics, Inc. 改进的用於治疗肌营养不良的组合物
AU2014300981B2 (en) 2013-06-27 2017-08-10 Ricc A/S Antisense oligomers and conjugates targeting PCSK9
TWI702046B (zh) 2013-07-19 2020-08-21 美商Ionis製藥公司 用於調節τ蛋白表現之組合物
KR20160083876A (ko) * 2013-11-14 2016-07-12 로슈 이노베이션 센터 코펜하겐 에이/에스 ApoB 안티센스 접합체 화합물
WO2015108048A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
WO2015108046A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
WO2015108047A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
WO2015107425A2 (en) * 2014-01-16 2015-07-23 Wave Life Sciences Pte. Ltd. Chiral design
TWI672314B (zh) 2014-03-12 2019-09-21 Nippon Shinyaku Co., Ltd. 反義核酸
JP2017521045A (ja) 2014-05-01 2017-08-03 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． アンジオポエチン様因子３発現を調節するための組成物及び方法
RU2695430C2 (ru) 2014-06-17 2019-07-23 Ниппон Синяку Ко., Лтд. Антисмысловые нуклеиновые кислоты
RU2708237C2 (ru) 2014-08-22 2019-12-05 Общество с ограниченной ответственностью "НооГен" Модифицированные олигонуклеотиды и способ их получения
MA43072A (fr) 2015-07-22 2018-05-30 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
WO2017047707A1 (ja) 2015-09-15 2017-03-23 日本新薬株式会社 アンチセンス核酸
EP3351634A4 (en) 2015-09-16 2019-05-08 Nippon Shinyaku Co., Ltd. ANTISENSE NUCLEIC ACID FOR THE TREATMENT OF AMYOTROPHY
US10373069B2 (en) 2015-09-26 2019-08-06 Intel Corporation Technologies for platform-targeted machine learning
MA46427A (fr) 2015-10-09 2018-08-15 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
US10108542B2 (en) * 2016-01-04 2018-10-23 Avalanche Technology, Inc. Serial link storage interface (SLSI) hybrid block storage
US20170210647A1 (en) * 2016-01-21 2017-07-27 Veolia Water Solutions & Technologies Support Process for reducing selenium from an ion-exchange or adsorption media brine
CA3015823A1 (en) 2016-03-13 2017-09-21 Wave Life Sciences Ltd. Compositions and methods for phosphoramidite and oligonucleotide synthesis
MA45290A (fr) * 2016-05-04 2019-03-13 Wave Life Sciences Ltd Procédés et compositions d'agents biologiquement actifs
MA45270A (fr) 2016-05-04 2017-11-09 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
JP2019520339A (ja) 2016-06-03 2019-07-18 ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． オリゴヌクレオチド、その組成物および方法
MX2018016253A (es) 2016-07-05 2019-09-09 Biomarin Tech Bv Oligonucleotidos de conmutacion o modulacion de empalme de pre-arnm que comprenden radicales de andamio biciclicos, con caracteristicas mejoradas para el tratamiento de trastornos geneticos.
WO2018014042A1 (en) 2016-07-15 2018-01-18 Ionis Pharmaceuticals, Inc. Compounds and methods for modulation of dystrophin transcript
WO2018022473A1 (en) 2016-07-25 2018-02-01 Wave Life Sciences Ltd. Phasing
RU2016138168A (ru) 2016-09-26 2018-03-29 Оксфордский Университет Аналоги олигонуклеотидов как средства коррекции сплайсинга для лечения мышечной дистрофии дюшена
US9763168B1 (en) * 2016-09-30 2017-09-12 T-Mobile Usa, Inc. Blocked device checking in roaming scenarios
EP3544987A4 (en) 2016-11-23 2020-11-18 Wave Life Sciences Ltd. COMPOSITIONS AND SYNTHESIS OF PHOSPHORAMIDITES AND OLIGONUCLEOTIDES
RU2740501C2 (ru) 2017-02-21 2021-01-14 Федеральное государственное бюджетное учреждение науки Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук (ИХБФМ СО РАН) МОДИФИЦИРОВАННЫЕ ОЛИГОНУКЛЕОТИДЫ, АКТИВИРУЮЩИЕ РНКазу Н
JP7557941B2 (ja) 2017-06-02 2024-09-30 ウェイブ ライフ サイエンシズ リミテッド オリゴヌクレオチド組成物及びその使用方法
CN111050806A (zh) 2017-06-02 2020-04-21 波涛生命科学有限公司 寡核苷酸组合物及其使用方法
CN120330183A (zh) 2017-06-02 2025-07-18 波涛生命科学有限公司 寡核苷酸组合物及其使用方法
WO2018237194A1 (en) 2017-06-21 2018-12-27 Wave Life Sciences Ltd. Compounds, compositions and methods for synthesis
WO2019002237A1 (en) 2017-06-28 2019-01-03 Roche Innovation Center Copenhagen A/S METHOD OF MULTIPLE COUPLING AND OXIDATION
AR112779A1 (es) 2017-08-08 2019-12-11 Wave Life Sciences Ltd Composiciones de nucleótidos y métodos relacionados
AU2018333065B2 (en) 2017-09-18 2024-04-18 Wave Life Sciences Ltd. Technologies for oligonucleotide preparation
JP2020537518A (ja) 2017-10-12 2020-12-24 ウェーブ ライフ サイエンシーズ リミテッド オリゴヌクレオチド組成物及びその方法

Also Published As

Publication number Publication date
WO2017062862A2 (en) 2017-04-13
CR20180233A (es) 2018-05-25
PE20181353A1 (es) 2018-08-22
PH12018500719A1 (en) 2018-10-01
IL295755A (en) 2022-10-01
TW201722439A (zh) 2017-07-01
AU2016334232B2 (en) 2022-05-26
WO2018067973A1 (en) 2018-04-12
CA3037548A1 (en) 2018-04-12
MX2018003992A (es) 2018-08-01
IL258230A (en) 2018-05-31
NZ781029A (en) 2025-07-25
KR20180056766A (ko) 2018-05-29
BR112018006636A2 (pt) 2018-10-23
EP3523437A1 (en) 2019-08-14
AU2017338986A1 (en) 2019-04-11
MA46427A (fr) 2018-08-15
CN108137492A (zh) 2018-06-08
JP7511326B2 (ja) 2024-07-05
CL2018000818A1 (es) 2018-08-17
US20240117347A1 (en) 2024-04-11
US20190127733A1 (en) 2019-05-02
IL258230B (en) 2022-09-01
CA2999772A1 (en) 2017-04-13
JP2025029016A (ja) 2025-03-05
ECSP18032914A (es) 2018-06-30
AU2022221483B2 (en) 2025-10-09
US10450568B2 (en) 2019-10-22
WO2017062862A8 (en) 2017-06-29
CO2018004758A2 (es) 2018-06-20
JP2022101563A (ja) 2022-07-06
CN108137492B (zh) 2021-12-21
BR112018006636B1 (pt) 2023-03-28
AU2016334232A1 (en) 2018-05-10
AU2022221483A1 (en) 2022-09-22
JP2018537952A (ja) 2018-12-27
HK1256225A1 (zh) 2019-09-20
MA46481A (fr) 2019-08-14
EP3523437A4 (en) 2020-06-17
SG10201912902TA (en) 2020-02-27
CN109983128A (zh) 2019-07-05
CN114533900A (zh) 2022-05-27
AU2025283518A1 (en) 2026-01-15
JP2019530698A (ja) 2019-10-24
NI201800045A (es) 2018-07-24
NZ741397A (en) 2025-07-25
EP3359523A4 (en) 2019-07-24
WO2017062862A3 (en) 2017-05-26
JP7696310B2 (ja) 2025-06-20
US20190390197A1 (en) 2019-12-26
US20190008986A1 (en) 2019-01-10
EP3359523A2 (en) 2018-08-15
MX2023009712A (es) 2023-09-15

Similar Documents

Publication Publication Date Title
SV2018005661A (es) Composiciones oligonucleotidicas y sus metodos
UY33826A (es) Proteínas de unión con dominios trivariables y sus usos
CR20120154A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
DOP2011000333A (es) Inmunoglobulina con dominio variable dual y usos de la mismas
MX2017009044A (es) Metodo para el tratamiento de malignidades.
CR11837A (es) Inmunoglobulinas con dominio variable dual y usos de la misma
DOP2014000084A (es) Inmunoligantes biespecificos dirigidos contra tnf e il-17
DOP2013000025A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
CR20130074A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
MX2018004515A (es) Agentes de anticuerpo especificos para cd19 humano y usos de los mismos.
ES2769863T8 (es) 7-hidroxi-cannabidivarín (7-OH-CBDV) para usar en el tratamiento de la epilepsia
CO6690781A2 (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
ECSP13012648A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
DOP2010000369A (es) Inmunoglobulinas con dominio variable dual y usos de la misma
UY33707A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
MX383715B (es) Formas sólidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y usos de las mismas.
CL2018001108A1 (es) Composiciones y métodos para transducción de tumores
MX2023006706A (es) Administracion transdermica de agentes grandes en composiciones de emulsion mediante acondicionamiento de la piel con microagujas y sus usos.
DOP2016000202A (es) Proteínas de fusión uti
CR20160316A (es) Compuestos derivados de hidroxiformamida y usos del mismo
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
ECSP13012523A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
AR110113A1 (es) Anticuerpo anti-selectina y sus usos
PE20180574A1 (es) Lisobactina para su uso en el tratamiento de la mastitis bovina
CL2018000336A1 (es) Composición para el tratamiento de la mucosidad en las branquias de los peces